Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
Editas Medicine (NASDAQ: EDIT), a gene editing company, has announced it will release its Q1 2025 financial results on May 12, 2025 through a press release and SEC filings. The company has discontinued its practice of hosting quarterly financial results conference calls.
Additionally, Editas management will participate in the Bank of America Global Healthcare Conference in Las Vegas on May 13, 2025 at 5:15 p.m. PT in a fireside chat format. The presentation will be accessible via webcast on the company's website, with a replay available for approximately 30 days.
Editas Medicine (NASDAQ: EDIT), un'azienda di editing genetico, ha annunciato che pubblicherà i suoi risultati finanziari del primo trimestre 2025 il 12 maggio 2025 tramite un comunicato stampa e documenti SEC. La società ha interrotto la consueta pratica di organizzare conference call per la presentazione trimestrale dei risultati finanziari.
Inoltre, il management di Editas parteciperà alla Bank of America Global Healthcare Conference a Las Vegas il 13 maggio 2025 alle 17:15 PT, in un formato fireside chat. La presentazione sarà disponibile in webcast sul sito web dell’azienda, con una replica accessibile per circa 30 giorni.
Editas Medicine (NASDAQ: EDIT), una empresa de edición genética, ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 el 12 de mayo de 2025 mediante un comunicado de prensa y presentaciones ante la SEC. La compañía ha dejado de realizar llamadas de conferencia trimestrales para presentar sus resultados financieros.
Además, la dirección de Editas participará en la Bank of America Global Healthcare Conference en Las Vegas el 13 de mayo de 2025 a las 5:15 p.m. PT en formato de conversación informal. La presentación estará disponible en webcast en el sitio web de la empresa, con una repetición accesible durante aproximadamente 30 días.
Editas Medicine (NASDAQ: EDIT)는 유전자 편집 회사로서 2025년 1분기 재무 실적을 2025년 5월 12일 보도자료와 SEC 제출 문서를 통해 발표할 예정입니다. 회사는 분기별 재무 실적 컨퍼런스 콜을 중단하였습니다.
또한, Editas 경영진은 2025년 5월 13일 오후 5시 15분(태평양 시간)에 라스베이거스에서 열리는 Bank of America Global Healthcare Conference에 파이어사이드 채팅 형식으로 참여할 예정입니다. 발표는 회사 웹사이트를 통해 웹캐스트로 제공되며, 약 30일간 다시보기 서비스가 제공됩니다.
Editas Medicine (NASDAQ: EDIT), une société spécialisée dans l'édition génétique, a annoncé qu'elle publiera ses résultats financiers du premier trimestre 2025 le 12 mai 2025 via un communiqué de presse et des dépôts auprès de la SEC. La société a cessé d'organiser des conférences téléphoniques trimestrielles pour présenter ses résultats financiers.
Par ailleurs, la direction d'Editas participera à la Bank of America Global Healthcare Conference à Las Vegas le 13 mai 2025 à 17h15 PT, sous la forme d'une discussion informelle (fireside chat). La présentation sera accessible en webcast sur le site internet de la société, avec une rediffusion disponible pendant environ 30 jours.
Editas Medicine (NASDAQ: EDIT), ein Unternehmen für Genom-Editing, hat angekündigt, seine Finanzergebnisse für das erste Quartal 2025 am 12. Mai 2025 per Pressemitteilung und SEC-Einreichungen zu veröffentlichen. Das Unternehmen hat die Praxis eingestellt, vierteljährliche Telefonkonferenzen zu den Finanzergebnissen abzuhalten.
Zusätzlich wird das Management von Editas am Bank of America Global Healthcare Conference in Las Vegas am 13. Mai 2025 um 17:15 Uhr PT in Form eines Fireside Chats teilnehmen. Die Präsentation wird über einen Webcast auf der Unternehmenswebsite zugänglich sein, mit einer Wiederholung für etwa 30 Tage.
- None.
- None.
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial results and business updates on May 12 via press release and SEC filings. As previously announced, the Company does not plan to host quarterly financial results conference calls moving forward.
Additionally, Editas Medicine management will participate in the following upcoming investor conference in May:
- Bank of America Global Healthcare Conference
Format: Fireside Chat
Date: Tuesday, May 13
Time: 5:15 p.m. PT
Location: Las Vegas, NV
To access the live webcast of Editas Medicine’s presentation, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the event.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Media and Investor Contact: ir@editasmed.com
FAQ
When will Editas Medicine (EDIT) release Q1 2025 earnings?
Will Editas Medicine (EDIT) host a Q1 2025 earnings call?
Where is Editas Medicine (EDIT) presenting at the Bank of America Healthcare Conference?
How can I access Editas Medicine's (EDIT) Bank of America conference presentation?
